BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Phase 2 Study of SAR302503 in Patients With Myelofibrosis
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT01420770
- Locations
- 🇺🇸
Investigational Site Number 840001, San Francisco, California, United States
🇺🇸Investigational Site Number 840003, Ann Arbor, Michigan, United States
🇺🇸Investigational Site Number 840006, Rochester, Minnesota, United States
Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12
- Registration Number
- NCT01413906
- Locations
- 🇯🇵
Local Institution, Kashiwa-shi, Chiba, Japan
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 123
- Registration Number
- NCT01404585
- Locations
- 🇺🇸
Pharma Resource, East Providence, Rhode Island, United States
🇺🇸Altoona Center For Clinical Research, Duncansville, Pennsylvania, United States
🇪🇸Local Institution, Sevilla, Spain
Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects
- Conditions
- HIV
- Interventions
- Drug: Atazanavir, powder for oral use 1 (POU1)
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2013-06-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12
- Registration Number
- NCT01404572
- Locations
- 🇺🇸
Pra International, Lenexa, Kansas, United States
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2015-01-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT01400451
- Locations
- 🇺🇸
University Of California Los Angeles, Los Angeles, California, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Dana Farber Cancer Inst, Boston, Massachusetts, United States
Japanese Phase 1 Multiple Ascending Dose (MAD) Study
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2013-06-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 57
- Registration Number
- NCT01396252
- Locations
- 🇯🇵
Local Institution, Taito-Ku, Tokyo, Japan
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT01393964
- Locations
- 🇺🇸
University Of Maryland, Baltimore, Maryland, United States
🇺🇸Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States
🇺🇸Tennessee Oncology, Pllc, Nashville, Tennessee, United States
Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
- Conditions
- Chronic Myeloid Leukemia
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT01394666
Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations
- Conditions
- Pharmacokinetic Study in Healthy Participants
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 141
- Registration Number
- NCT01392703
- Locations
- 🇺🇸
Healthcare Discoveries Inc., San Antonio, Texas, United States
BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 448
- Registration Number
- NCT01389323
- Locations
- 🇺🇸
Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇺🇸Triple O Research Institute, P.A., West Palm Beach, Florida, United States
🇺🇸University Of Miami, Miami, Florida, United States